Eyal Meiri, MD
Fax: (404) 367-7653
Business hours
| Monday | 8:00am to 4:30pm |
| Tuesday | 8:00am to 4:30pm |
| Wednesday | 8:00am to 4:30pm |
| Thursday | 8:00am to 4:30pm |
| Friday | 8:00am to 4:30pm |
| Saturday | - |
| Sunday | - |
About us
Dr. Eyal Meiri earned his medical degree from University of Toronto and completed his residency at Sinai Hospital of Detroit. He is fellowship-trained in oncology and hematology and is board certified in Internal Medicine and Medical Oncology. Prior to joining Piedmont, he was the Chief of Medical Oncology at Cancer Treatment Centers of America. Dr. Meiri has been practicing medicine for over 33 years and specializes in GI Cancers and Neuroendocrine Tumors. In his spare time, Dr. Meiri enjoys spending time reading, listening to audio books and podcasts, traveling, the Toronto Maple Leafs, and live concerts. Dr. Meiri is accepting new patients and welcomes most major insurance plans.
Schedule an Appointment Today!
| Languages | English |
| Tags | abdominal cancer, abdominal cancer chemotherapy, adenocarcinoma of the bladder, adjuvant chemotherapy, adolescent and young adult cancer (aya), advanced malignancies, anal cancer chemotherapy, anaplastic cancer of thyroid, androgen deprivation therapy, anorectal cancer chemotherapy, appendiceal cancer chemotherapy, autoimmune cytopenia, biliary tract cancer chemotherapy, brain metastases, breast cancer chemotherapy, cancer, cancer chemotherapy, cancer during pregnancy, cancer genomics, cancer immunotherapy, cancer of the joints, cancer of the muscles, cancer pain, cancer related fatigue, cancer risk, cancer survivor, carcinoma of unknown primary, cervical and endometrial cancers, cervical cancer, cervical cancer chemotherapy, chemoradiation, cholangiocarcinoma, clinical trials, colon cancer chemotherapy, colon cancer genomics, colorectal cancer chemotherapy, colorectal malignancy, cowden syndrome, diaphragm cancer, egfr mutation, egfr translocation, electrolyte abnormalities in cancer patients, endometrial cancer chemotherapy, esophageal cancer, esophageal cancer chemotherapy, eye cancer, eye cancer chemotherapy, eyelid cancer, eyelid cancer chemotherapy, face cancer, familial renal cell carcinoma, fibrolamellar carcinoma, gallbladder cancer, gallbladder cancer chemotherapy, gallbladder cancer genomics, gastroesophageal junction cancer, gastrointestinal (gi) cancer, gastrointestinal (gi) cancer genomics, gastrointestinal (gi) stromal tumors, germinoma, gleason score, glottic cancer, head and neck cancer chemotherapy, hepatic artery infusion pump placement, hereditary kidney cancer, hereditary papillary renal cell cancer, histiocytoma, human t-cell lymphotropic virus type 1, human t-cell lymphotropic virus type 2, hypopharyngeal cancer chemotherapy, immunoassay for tumor antigen ca 125, immunoassay for tumor antigen ca 15-3 and ca 27-29, intestinal cancer, intravesical chemotherapy, kidney cancer, lacrimal gland cancer, large cell cancer of the lung, large cell neuroendocrine tumors, laryngeal cancer chemotherapy, liquid biopsy testing, liver cancer, liver cancer chemotherapy, liver cancer genomics, liver metastases, lung cancer, lung metastasis, malignant carcinoid tumor of colon, malignant granular cell tumor, malignant lung tumors, malignant spindle cell neoplasm, mediastinal lymphadenopathy, medullary cancer of thyroid, melanoma surgery, metastatic rib cancer, microsatellite instability, mouth cancer chemotherapy, multi-cancer early detection blood test, muscle invasive bladder cancer, nasopharyngeal cancer chemotherapy, neuroendocrine tumors |
| Video | https://www.youtube.com/watch?v=7shtiPlVQTg |